Allele Specific Expression of the Transthyretin Gene in Swedish Patients with Hereditary Transthyretin Amyloidosis (ATTR V30M) Is Similar between the Two Alleles

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Norgren, Nina ^a   Hellman, Urban ^a   Ericzon, Bo Göran ^b   Olsson, Malin ^a   Suhr, Ole B ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

LUCIFERASE; MICRORNA; PREALBUMIN;

3' UNTRANSLATED REGION; ALLELE; AMYLOIDOSIS; ANIMAL CELL; ARTICLE; BIOASSAY; CELL STRAIN COS7; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC TRANSFECTION; GENETIC VARIABILITY; HEREDITARY TRANSTHYRETIN AMYLOIDOSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER BIOPSY; NONHUMAN; PENETRANCE; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; TRANSTHYRETIN GENE;

3' UNTRANSLATED REGIONS; AGED; ALLELES; AMYLOID; AMYLOID NEUROPATHIES, FAMILIAL; BINDING SITES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; MALE; MICRORNAS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PREALBUMIN; PROTEOLYSIS; SWEDEN;

EID: 84869792701     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049981     Document Type: Article

References (20)

1. Kelly JW, Colon W, Lai Z, Lashuel HA, McCulloch J, et al. (1997) Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv Protein Chem 50: 161-181.
2. Plante-Bordeneuve V, Said G, (2011) Familial amyloid polyneuropathy. Lancet Neurol 10: 1086-1097.
3. Plante-Bordeneuve V, Carayol J, Ferreira A, Adams D, Clerget-Darpoux F, et al. (2003) Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese families. J Med Genet 40: e120.
4. Hellman U, Alarcon F, Lundgren HE, Suhr OB, Bonaiti-Pellie C, et al. (2008) Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 15: 181-186.
5. Coelho T ML, Martins A, Waddington Cruz M, Planté-Bordeneuve V, Suhr OB, et al. (2011) The long-term effects of tafamidis for the treatment of transthyretin type familial amyloid polyneuropathy. VIIIth International Symposium on Familial Amyloidotic Polyneuropathy.
6. Coelho T SO, Adams D, Lozeron P, Hawkins P, Mant T, et al. (2011) Phase I safety, pharmacokinetic and pharmacodynamic results for ALN-TTR01, a novel RNAi therapeutic for the treatment of transthyretin amyloidosis. VIIIth International Symposium on Familial Amyloidotic Polyneuropathy. Kumamoto, Japan.
7. Monia BP AE, Guo S, Benson MD (2011) Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. VIIIth International Symposium on Familial Amyloidotic Polyneuropathy. Kumamoto, Japan.
8. Kwak PB, Iwasaki S, Tomari Y, (2010) The microRNA pathway and cancer. Cancer Sci 101: 2309-2315.
9. Liu Z, Wei S, Ma H, Zhao M, Myers JN, et al. (2011) A functional variant at the miR-184 binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 32: 1668-1674.
10. Amin AS, Giudicessi JR, Tijsen AJ, Spanjaart AM, Reckman YJ, et al. (2011) Variants in the 3′ untranslated region of the KCNQ1-encoded Kv7.1 potassium channel modify disease severity in patients with type 1 long QT syndrome in an allele-specific manner. Eur Heart J.
11. Wang G, van der Walt JM, Mayhew G, Li YJ, Zuchner S, et al. (2008) Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet 82: 283-289.
12. Laguette MJ, Abrahams Y, Prince S, Collins M, (2011) Sequence variants within the 3′-UTR of the COL5A1 gene alters mRNA stability: implications for musculoskeletal soft tissue injuries. Matrix Biol 30: 338-345.
13. Olsson M, Norgren N, Obayashi K, Plante-Bordeneuve V, Suhr OB, et al. (2010) A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers. BMC Med Genet 11: 130.
14. Soares ML, Coelho T, Sousa A, Holmgren G, Saraiva MJ, et al. (2004) Haplotypes and DNA sequence variation within and surrounding the transthyretin gene: genotype-phenotype correlations in familial amyloid polyneuropathy (V30M) in Portugal and Sweden. Eur J Hum Genet 12: 225-237.
15. Holmgren G, Lundgren E, Kangawa K, Kurihara T, Matsukura S, et al. (1993) Diagnostic radioimmunoassay and DNA-analysis in Swedish and Japanese patients with familial amyloidotic polyneuropathy. Homozygosity for the TTR met30 gene. Acta Neurol Scand 87: 124-127.
16. Suhr OB, Ando Y, Ohlsson PI, Olofsson A, Andersson K, et al. (1998) Investigation into thiol conjugation of transthyretin in hereditary transthyretin amyloidosis. Eur J Clin Invest 28: 687-692.
17. Ueda M, Misumi Y, Mizuguchi M, Nakamura M, Yamashita T, et al. (2009) SELDI-TOF mass spectrometry evaluation of variant transthyretins for diagnosis and pathogenesis of familial amyloidotic polyneuropathy. Clin Chem 55: 1223-1227.
18. Sato T, Susuki S, Suico MA, Miyata M, Ando Y, et al. (2007) Endoplasmic reticulum quality control regulates the fate of transthyretin variants in the cell. EMBO J 26: 2501-2512.
19. Hanes D, Zech LA, Murrell J, Benson MD, (1996) Metabolism of normal and Met30 transthyretin. Adv Food Nutr Res 40: 149-155.
20. Ribeiro-Silva C, Gilberto S, Gomes RA, Mateus E, Monteiro E, et al. (2011) The relative amounts of plasma transthyretin forms in familial transthyretin amyloidosis: a quantitative analysis by Fourier transform ion-cyclotron resonance mass spectrometry. Amyloid 18: 191-199.